News

CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

Jan 20, 2021

This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA delay in an interview with Redeye.

IDL’s China visit highlights opportunities for growth

IDL Diagnostics recently met with CLIA partner Zecen, and its Chinese distributors Vastec, Sysmex and Fosun, to discuss market opportunities and portfolio development. Discussions highlighted China’s national pricing-code framework, expected to be implemented by the...

read more